Completed PHASE2 INTERVENTIONAL NCT01342146

Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children (PD)

Efficiency and Safety of Pegylated Somatropin(PEG-somatropin) in the Treatment of Children With Growth Hormone Deficiency: a Multicenter, Randomized, Open-label, Controlled Phase 2 Study

Sponsor: Capital Medical University

Conditions Growth Hormone Deficiency

Interventions Jintropin AQ pegylated Somatropin

Updated 7 times since 2017 Last updated: Jul 27, 2017 Started: May 31, 2006 Primary completion: Jan 31, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Growth Hormone Deficiency and is currently completed. Capital Medical University leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Sep 2023 — Oct 2023 [monthly]

Completed PHASE2
Jan 2021 — Sep 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Capital Medical University
Changchun GeneScience Pharmaceutical Co., Ltd.
Children's Hospital of Fudan University
First Affiliated Hospital, Sun Yat-Sen University
Huazhong University of Science and Technology

Data source: Changchun GeneScience Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.